Eventually RVMD reached the $30B marketcap by itself with an approximate SP of $145.
Starting from 2035 their product portfolio was expected to generate $10B in yearly sales and according to Gemini that number hasn't changed at all in the meantime.
RVMD has an average analyst price target of $187.29 ($263.00 being the highest), including 16 buy and 4 strong buy recommendations.
https://finance.yahoo.com/quote/RVMD/
Conclusion: Cytodyn shareholders and management, know the bare minimum value of prerevenue and pre-approval Leronlimab which cannot be below $60B if the ongoing trials do confirm.